Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Autism Prevalence is Now 1 in 44, Signifying the Eighth Increase in Prevalence Rates Reported by the CDC Since 2000


IRVINE, Calif., Dec. 2, 2021 /PRNewswire/ -- The Autism Community in Action (TACA) shared the Center for Disease Control and Prevention (CDC) reports, autism prevalence has taken another jump in the wrong direction. A once rare disability in 1970 at 1 to 2 in every 10,000 U.S. children has continued to rise to 1 in 44 U.S. children.  Since 2000, this is the eighth increase in the autism prevalence rate as released by the CDC in their "Autism and Developmental Disabilities Monitoring Network" (ADDM) report.

"A prevalence rate of 1 in 44 can no longer be ignored.  We cannot continue to overlook this epidemic." Lisa Ackerman.

"Since TACA started over 21 years ago, there have been ten autism prevalence numbers announced by the CDC. With each increase, I hope this number will provoke more people to care," said Lisa Ackerman, Founder and Executive Director of TACA. "The CDC prevalence figure is based on similar methodology and represents a true increase. It is not because we are better at diagnosing autism. There is just more autism. This prevalence rate means even more parents are being told their child has autism. A prevalence rate of 1 in 44 can no longer be ignored. Families are counting on us to act and support them.  We cannot continue to overlook this epidemic."

Autism is so prevalent today that almost every U.S. citizen has someone in their direct family who is affected by autism, they know someone with autism, or they know a family who is affected by autism.

Autism Fast Facts:

The Autism Community in Action (TACA) is a national non-profit organization dedicated to educating and supporting families affected by autism.  With 1 in 44 children in the United States diagnosed with autism, support for families is needed now more than ever before. TACA's mission to provide education, support and hope to families living with autism with the goal of independence and/or recovery.

About The Autism Community in Action (TACA)  
The Autism Community in Action (TACA) is a national nonprofit 501(c)(3) organization founded in 2000 with the mission to provide education, support and hope to families living with autism.  Headquartered in Irvine, Calif. with staff and volunteers working across the country annually serving over 75,000 families and adding 700 new families every month. TACA offers free educational meetings, webinars, parent mentor program, an online Hope and Help support group, two annual National Autism Conferences hosted on the west and east coasts and a free 200-page Autism Journey Guide given to new families at events. TACA has a social media presence of over 365,000 on Facebook, Instagram, Twitter, and YouTube.

For more information visit www.tacanow.org.

 

SOURCE The Autism Community in Action (TACA)


These press releases may also interest you

at 03:01
Nova Mentis Life Science Corp. ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company...

at 03:00
SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor. Distinguished Professor of Medicine and Medical and Molecular Genetics at...

at 03:00
iSwap, a cross-chain transaction platform, announced the launch of iSwap V5, the latest upgrade to its system today. Through this upgrade, iSwap aims to improve the user experience for cross-chain DeFi transactions. The upgrade consists of two...

at 03:00
NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2021. This is Dr. Daruwala's sixth consecutive year being reviewed and approved by NJ Top Docs. Dr. Daruwala is a board certified...

at 02:23
Ready to capitalize on a strong foundation Q4 2021 highlights Total net revenues of SEK 144.0 m (159.2) Net earnings of SEK -66.0 m (-49.6) EBITDA of SEK -48.5 m (1.0) US Pharma segment (ZUBSOLV® US) net revenues of SEK 133.6 m (143.1), in local...

at 02:15
Epizyme, Inc. , a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced the pricing of an underwritten public offering of 56,666,667 shares of its common stock at a price to...



News published on 2 december 2021 at 18:39 and distributed by: